RIFF Inhibitors
Chemical inhibitors of RIFF function through various mechanisms to impede its activity by targeting different signaling pathways that regulate the protein's functionality. KU-0063794 is one such inhibitor that exerts its effect by directly inhibiting mTORC1 and mTORC2 complexes, which are upstream regulators of the PI3K/Akt/mTOR pathway, a signaling cascade involved in controlling RIFF activity. Similarly, AZD8055 and Rapamycin also target these mTOR complexes, thereby constraining the signaling that contributes to the functional activity of RIFF. Another compound, LY294002, along with Wortmannin, shuts down PI3K, thereby preventing the activation of the Akt pathway and the subsequent phosphorylation events that would enhance RIFF activity. PD173074 takes a different approach by inhibiting FGFR tyrosine kinase, subsequently curbing the MAPK and PI3K/Akt signaling pathways that are upstream of RIFF, leading to a reduction in its activity.
Further inhibitory actions are seen with SP600125 and SB203580, which target JNK and p38 MAP kinase, respectively. These kinases are involved in cellular responses to stress and cytokines, which can modulate RIFF activity. By inhibiting these kinases, SP600125 and SB203580 can suppress RIFF activation mediated by stress-related signaling events. U0126, a MEK1/2 inhibitor, decreases RIFF activity by reducing the phosphorylation of ERK, an essential component of the MAPK pathway that regulates RIFF. SL0101, targeting RSK in the MAPK pathway, prevents the phosphorylation events that would otherwise enhance RIFF activity. Lastly, ZM-447439, an inhibitor of Aurora kinases, can affect RIFF activity indirectly by disrupting cell cycle progression, a process to which RIFF is connected. Each chemical, through its unique mode of action, contributes to the modulation of RIFF activity by targeting specific signaling nodes and pathways that are crucial for its regulation.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
KU 0063794 | 938440-64-3 | sc-361219 | 10 mg | $209.00 | ||
KU-0063794 directly inhibits mTORC1 and mTORC2 complexes, which are upstream regulators in the PI3K/Akt/mTOR pathway. Since RIFF has been shown to be regulated by the Akt pathway, inhibiting mTOR can reduce RIFF activity by decreasing Akt-mediated phosphorylation events that would otherwise enhance RIFF function. | ||||||
PD173074 | 219580-11-7 | sc-202610 sc-202610A sc-202610B | 1 mg 5 mg 50 mg | $46.00 $140.00 $680.00 | 16 | |
PD173074 is a selective inhibitor of the FGFR tyrosine kinase, which can inhibit the downstream MAPK and PI3K/Akt signaling pathways. This can hinder the phosphorylation and activation of RIFF, which may be regulated by these pathways. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 inhibits PI3K, a key component of the PI3K/Akt signaling pathway. By inhibiting PI3K, LY294002 can prevent the phosphorylation and activation of Akt, which could lead to a reduction in RIFF activity due to decreased Akt-mediated signaling. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which is involved in regulatory processes that can include RIFF. By inhibiting JNK activity, SP600125 can reduce the functional activity of RIFF by preventing JNK-mediated regulatory phosphorylation steps that would promote RIFF activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 selectively inhibits p38 MAP kinase, which is involved in cellular responses to cytokines and stress. RIFF activity can be modulated by stress-activated pathways, and by inhibiting p38 MAP kinase, SB203580 can suppress the activation of RIFF that may be mediated by stress-related signaling events. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK1/2, which are upstream of ERK in the MAPK pathway. RIFF can be regulated by ERK signaling, and by inhibiting MEK1/2, U0126 can reduce the phosphorylation and activation of ERK, leading to a decrease in RIFF activity as ERK-mediated signaling events are suppressed. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent inhibitor of PI3K, which is crucial for the PI3K/Akt pathway. By inhibiting PI3K, Wortmannin can prevent the activation of downstream targets, including Akt, which can lead to a decrease in RIFF functional activity as Akt-mediated signaling is suppressed. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits the mTOR pathway by binding to FKBP12 and targeting mTORC1. The mTOR pathway is involved in cellular growth and proliferation, processes in which RIFF may play a role. By inhibiting mTORC1, Rapamycin can decrease the activity of RIFF by reducing the mTOR-mediated signaling events that would otherwise enhance RIFF function. | ||||||
SL 0101-1 | 77307-50-7 | sc-204287 sc-204287A sc-204287B sc-204287C sc-204287D | 1 mg 10 mg 25 mg 50 mg 100 mg | $200.00 $353.00 $772.00 $1230.00 $2070.00 | 3 | |
SL0101 is an inhibitor of RSK (p90 ribosomal S6 kinase), which is involved in the downstream signaling of the MAPK pathway. As RIFF may be influenced by RSK-mediated phosphorylation events, inhibiting RSK with SL0101 can decrease RIFF activity by preventing such phosphorylation. | ||||||
AZD8055 | 1009298-09-2 | sc-364424 sc-364424A | 10 mg 50 mg | $160.00 $345.00 | 12 | |
AZD8055 is a potent inhibitor of both mTORC1 and mTORC2. These mTOR complexes are part of the signaling pathways that regulate cell growth and proliferation, which RIFF may influence. Inhibition of these complexes by AZD8055 can lead to reduced RIFF activity by limiting the mTOR-mediated signaling that would otherwise contribute to RIFF function. | ||||||